Safety and side effects are still being screened
y 5-9 dlares para la metformina en 30 das) 151
Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease
Important safety considerations include monitoring for signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder disease, and hypoglycemia, particularly in patients taking concurrent diabetes medications
Well, that patient will still qualify for this program